Developer docs
API playgroundTry for free, no card

Search company profiles

Biogaran

Full company profile

uuid000bvps

Namestring
Biogaran
Legal namestring
Biogaran
Websiteurl
biogaran.fr
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Biogaran is a French pharmaceutical laboratory founded in 1996, headquartered in Colombes, France, and currently owned by British private equity firm BC Partners following a 2025 divestiture from Servier. The company specializes in generic prescription medications, distributed nationally through French pharmacies under partial or full reimbursement by the French social security system. Its product portfolio spans five primary categories: generic prescription medications, OTC self-care products marketed under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. The company also runs adjunct patient-support initiatives such as Mon Bracelet Biogaran (adherence), Mon Urgence Pilule, Biog'Stories, and oncology and aging-at-home programs, plus content publishing through Le Mag Biogaran.

Biogaran's business model is built on volume-driven sales of generics and OTC products through the nationwide French pharmacy channel, with pharmacists serving as both distribution and counseling touchpoints. Marketing is multi-channel (TV, social platforms, content, experiential events), and consumer-facing brand equity has been recognized via the 'marque préférée des Français' designation. Pricing is governed by French reimbursement frameworks for prescription products and out-of-pocket purchase for OTC items; pricing is not publicly disclosed. The company employs 101-250 people and reports a 30-year operational history.

In 2026, Biogaran extended beyond small-molecule generics into the ophthalmology biosimilar segment via a co-commercialization partnership with Sandoz and Lupin for Ranluspec (ranibizumab biosimilar) in France. The company has no disclosed AI/ML, APIs, or technology platform beyond manufacturing and formulation capabilities, and relies on regulatory compliance, brand, and pharmacy distribution as its principal assets.

Short descriptiontext

Biogaran is a French pharmaceutical laboratory, founded in 1996 and owned by BC Partners, that manufactures and distributes generic prescription medications, OTC products (Biogaran Conseil), medical devices, cosmetics, and dietary supplements through France's nationwide pharmacy network to patients, pharmacists, and prescribers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersColombes, France
HQ citystring
Colombes
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic medications, pharmaceutical manufacturing, over-the-counter healthcare, biosimilar drugs, pharmacy distribution
Industry3 codes
PRIMARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Generic Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Medications
TypeOne Time License
Description

Sale of generic prescription medications through pharmacy networks across France

biogaran.fr
2OTC Products (Biogaran Conseil)
TypeOne Time License
Description

Over-the-counter medications and self-medication products sold without prescription through pharmacies

biogaran.fr
3Health Content and Services
TypeSubscription Recurring
Description

Patient education content and digital health services including health articles, vaccination information, and wellness guidance

biogaran.fr
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Prescription generic medications
ModelOtherBilling cadencePay-as-you-go
Notes

Prescription generic medications sold through pharmacies with partial or full reimbursement under French social security

biogaran.fr
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Biogaran Conseil
Description

Over-the-counter (OTC) medication and health product line sold without prescription, featuring packaging campaigns and pharmacy partnerships.

biogaran.fr
Core offering1 text field

Biogaran is a French pharmaceutical laboratory that manufactures and distributes generic prescription medications, over-the-counter (OTC) health products under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. Products are sold primarily through the French pharmacy network, with partial or full reimbursement under French social security, complemented by patient education content (Le Mag) and pharmacovigilance services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 88% of respondents in Ifop study have purchased OTC medications
+1 more record
Product overview1 text field

Biogaran is a French pharmaceutical laboratory specializing in generic medications and health products since 1996. The company operates a diversified portfolio organized around five product categories: generic prescription medications (Médicaments), medical devices (Dispositifs Médicaux), cosmetics (Cosmétiques), dietary supplements (Compléments Alimentaires), and over-the-counter products under the Biogaran Conseil sub-brand. Beyond pharmaceutical products, Biogaran offers patient support initiatives including Mon Bracelet Biogaran (treatment adherence tool), Mon Urgence Pilule (emergency contraception info), Biog'Stories (patient storytelling), and Contre le Cancer On Fait Equipe (cancer support). The company also provides health education through Le Mag and maintains pharmacovigilance services. Recently, Biogaran expanded into biosimilars through a partnership with Lupin and Sandoz for the distribution of Ranluspec in France.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Sandoz handles commercialization of Lupin's biosimilar Ranluspec across the European Union excluding Germany. Biogaran co-commercializes the product in France, strengthening distribution capabilities for this ophthalmology biosimilar treatment.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership where Sandoz commercializes Ranluspec (biosimilar ranibizumab) across EU excluding Germany, with Biogaran handling distribution in France for eye condition treatments.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Stada is a European-focused generics and consumer healthcare company with a similar OTC + generics dual model. Comparable business model and go-to-market through European pharmacy networks; previously PE-owned, mirroring Biogaran's ownership profile.

2Laboratoires Servier
TypeBroad incumbent
Description

Servier is Biogaran's former parent and a major French pharmaceutical group with branded specialty drugs. Comparable as a French pharma operator with pharmacy-channel reach; broader portfolio (innovative branded drugs) but historically the same corporate parent.

3Arrow Génériques (Aurobindo)
TypeDirect peer
Description

Arrow Génériques is the European generics arm of Aurobindo and a direct France-market competitor in generic prescriptions through pharmacy distribution. Closely comparable on therapeutic coverage and pharmacy-channel model.

TypeDirect peer
Description

Krka is a Slovenian generics manufacturer with significant Western European sales. Comparable on generic prescription drugs, OTC consumer health products, and pharmacy-channel distribution model across continental Europe.

TypeDirect peer
Description

Almus is the generics brand of Accord Healthcare, a major European generic player competing in pharmacy channels across France. Comparable on generics portfolio breadth and pharmacy-channel go-to-market.

6Sandoz
TypeDirect peer
Description

Sandoz is the global leader in generic pharmaceuticals and biosimilars, spun out of Novartis. Directly comparable as a generic and biosimilar manufacturer/distributor; Biogaran actually partners with Sandoz to co-commercialize Ranluspec in France, confirming channel and portfolio overlap.

TypeDirect peer
Description

EG Labo is the French generics subsidiary of Stada and a head-to-head competitor in the French pharmacy generics market. Closely comparable on domestic French market positioning, generics portfolio, and pharmacy-distribution model.

TypeDirect peer
Description

Teva is one of the world's largest generic drug manufacturers with a strong European footprint. Directly comparable on generics manufacturing, OTC portfolio, and biosimilars; competes head-to-head in France and broader Europe.

TypeDirect peer
Description

Viatris is a global generics and specialty pharma company with deep European presence. Comparable on generic prescription and OTC distribution, broad therapeutic coverage, and biosimilar ambitions; competes with Biogaran across French pharmacy channel.

TypeDirect peer
Description

Zentiva is a European generics manufacturer headquartered in Prague with strong presence in France. Closely comparable as a European-branded generics specialist serving pharmacy channels with a similar portfolio breadth and reimbursement-driven model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biogaran

Generic Pharmaceuticalsbiogaran.fr

Biogaran is a French pharmaceutical laboratory, founded in 1996 and owned by BC Partners, that manufactures and distributes generic prescription medications, OTC products (Biogaran Conseil), medical devices, cosmetics, and dietary supplements through France's nationwide pharmacy network to patients, pharmacists, and prescribers.

What Biogaran does

Biogaran is a French pharmaceutical laboratory founded in 1996, headquartered in Colombes, France, and currently owned by British private equity firm BC Partners following a 2025 divestiture from Servier. The company specializes in generic prescription medications, distributed nationally through French pharmacies under partial or full reimbursement by the French social security system. Its product portfolio spans five primary categories: generic prescription medications, OTC self-care products marketed under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. The company also runs adjunct patient-support initiatives such as Mon Bracelet Biogaran (adherence), Mon Urgence Pilule, Biog'Stories, and oncology and aging-at-home programs, plus content publishing through Le Mag Biogaran.

Biogaran's business model is built on volume-driven sales of generics and OTC products through the nationwide French pharmacy channel, with pharmacists serving as both distribution and counseling touchpoints. Marketing is multi-channel (TV, social platforms, content, experiential events), and consumer-facing brand equity has been recognized via the 'marque préférée des Français' designation. Pricing is governed by French reimbursement frameworks for prescription products and out-of-pocket purchase for OTC items; pricing is not publicly disclosed. The company employs 101-250 people and reports a 30-year operational history.

In 2026, Biogaran extended beyond small-molecule generics into the ophthalmology biosimilar segment via a co-commercialization partnership with Sandoz and Lupin for Ranluspec (ranibizumab biosimilar) in France. The company has no disclosed AI/ML, APIs, or technology platform beyond manufacturing and formulation capabilities, and relies on regulatory compliance, brand, and pharmacy distribution as its principal assets.

Biogaran firmographics

Firmographics
Name
Biogaran
Legal name
Biogaran
Website
https://biogaran.fr
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Biogaran is a French pharmaceutical laboratory, founded in 1996 and owned by BC Partners, that manufactures and distributes generic prescription medications, OTC products (Biogaran Conseil), medical devices, cosmetics, and dietary supplements through France's nationwide pharmacy network to patients, pharmacists, and prescribers.
Ownership category
akta.pro rank

Biogaran industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Generic medications
  • Pharmaceutical manufacturing
  • Over-the-counter healthcare
  • Biosimilar drugs
  • Pharmacy distribution

Where Biogaran is headquartered

Location

Headquarters

HQ city
Colombes
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Biogaran business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Generic Medications: Sale of generic prescription medications through pharmacy networks across France
  2. OTC Products (Biogaran Conseil): Over-the-counter medications and self-medication products sold without prescription through pharmacies
  3. Health Content and Services: Patient education content and digital health services including health articles, vaccination information, and wellness guidance

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription generic medications

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Biogaran product offering

Product offering

Core offering

Biogaran is a French pharmaceutical laboratory that manufactures and distributes generic prescription medications, over-the-counter (OTC) health products under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. Products are sold primarily through the French pharmacy network, with partial or full reimbursement under French social security, complemented by patient education content (Le Mag) and pharmacovigilance services.

Product overview

Biogaran is a French pharmaceutical laboratory specializing in generic medications and health products since 1996. The company operates a diversified portfolio organized around five product categories: generic prescription medications (Médicaments), medical devices (Dispositifs Médicaux), cosmetics (Cosmétiques), dietary supplements (Compléments Alimentaires), and over-the-counter products under the Biogaran Conseil sub-brand. Beyond pharmaceutical products, Biogaran offers patient support initiatives including Mon Bracelet Biogaran (treatment adherence tool), Mon Urgence Pilule (emergency contraception info), Biog'Stories (patient storytelling), and Contre le Cancer On Fait Equipe (cancer support). The company also provides health education through Le Mag and maintains pharmacovigilance services. Recently, Biogaran expanded into biosimilars through a partnership with Lupin and Sandoz for the distribution of Ranluspec in France.

Differentiator

Problem solved

Functional benefit

Brands

  • Biogaran Conseil: Over-the-counter (OTC) medication and health product line sold without prescription, featuring packaging campaigns and pharmacy partnerships.

Quantifiable outcome

  • 88% of respondents in Ifop study have purchased OTC medications
  • +1 more outcomes

Companies that use Biogaran

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Biogaran technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biogaran partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SandozcoreChannel Partner/ Reseller/ Distributor · 23 February 2026Sandoz handles commercialization of Lupin's biosimilar Ranluspec across the European Union excluding Germany. Biogaran co-commercializes the product in France, strengthening distribution capabilities for this ophthalmology biosimilar treatment.
  • SandozcoreChannel Partner/ Reseller/ DistributorDistribution partnership where Sandoz commercializes Ranluspec (biosimilar ranibizumab) across EU excluding Germany, with Biogaran handling distribution in France for eye condition treatments.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Biogaran competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: Stada is a European-focused generics and consumer healthcare company with a similar OTC + generics dual model. Comparable business model and go-to-market through European pharmacy networks; previously PE-owned, mirroring Biogaran's ownership profile.
  • Arrow Génériques (Aurobindo): Arrow Génériques is the European generics arm of Aurobindo and a direct France-market competitor in generic prescriptions through pharmacy distribution. Closely comparable on therapeutic coverage and pharmacy-channel model.
  • Krka: Krka is a Slovenian generics manufacturer with significant Western European sales. Comparable on generic prescription drugs, OTC consumer health products, and pharmacy-channel distribution model across continental Europe.
  • Almus (Accord Healthcare): Almus is the generics brand of Accord Healthcare, a major European generic player competing in pharmacy channels across France. Comparable on generics portfolio breadth and pharmacy-channel go-to-market.
  • Sandoz: Sandoz is the global leader in generic pharmaceuticals and biosimilars, spun out of Novartis. Directly comparable as a generic and biosimilar manufacturer/distributor; Biogaran actually partners with Sandoz to co-commercialize Ranluspec in France, confirming channel and portfolio overlap.
  • EG Labo (Stada group): EG Labo is the French generics subsidiary of Stada and a head-to-head competitor in the French pharmacy generics market. Closely comparable on domestic French market positioning, generics portfolio, and pharmacy-distribution model.
  • Teva Pharmaceutical Industries: Teva is one of the world's largest generic drug manufacturers with a strong European footprint. Directly comparable on generics manufacturing, OTC portfolio, and biosimilars; competes head-to-head in France and broader Europe.
  • Viatris (formerly Mylan): Viatris is a global generics and specialty pharma company with deep European presence. Comparable on generic prescription and OTC distribution, broad therapeutic coverage, and biosimilar ambitions; competes with Biogaran across French pharmacy channel.
  • Zentiva: Zentiva is a European generics manufacturer headquartered in Prague with strong presence in France. Closely comparable as a European-branded generics specialist serving pharmacy channels with a similar portfolio breadth and reimbursement-driven model.

Broad incumbents

  • Laboratoires Servier: Servier is Biogaran's former parent and a major French pharmaceutical group with branded specialty drugs. Comparable as a French pharma operator with pharmacy-channel reach; broader portfolio (innovative branded drugs) but historically the same corporate parent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

Biogaran social profiles

Digital presence

Biogaran financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biogaran leadership team

Management profile

Number of profiles

Biogaran funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biogaran M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogaran

What does Biogaran do?

Biogaran is a French pharmaceutical laboratory that manufactures and distributes generic prescription medications, over-the-counter (OTC) health products under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. Products are sold primarily through the French pharmacy network, with partial or full reimbursement under French social security, complemented by patient education content (Le Mag) and pharmacovigilance services.

Is Biogaran a public or private company?

Biogaran is a private company. It is classified as private equity controlled and is currently operating.

When was Biogaran founded?

Biogaran was founded in 1996. It employs 501 to 1,000 people.

Where is Biogaran based?

Biogaran is headquartered in Colombes, France, in the Europe region.

How does Biogaran make money?

Three revenue lines are on record. Generic Medications are the primary driver. The others are OTC Products (Biogaran Conseil) and health Content and Services.

Who are Biogaran's main competitors?

Direct peers on record are Stada Arzneimittel, Arrow Génériques (Aurobindo), Krka, Almus (Accord Healthcare), Sandoz, EG Labo (Stada group), Teva Pharmaceutical Industries, Viatris (formerly Mylan) and Zentiva. Laboratoires Servier is listed as a broad incumbent.

Does Biogaran have an API?

No public API is recorded for Biogaran.

What industry is Biogaran in?

Biogaran's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is CRAOAHAB, OTC Medicines & Consumer Health Products Distribution, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CT CorporationBiogaran v. Lundbeck and the Challenger's Burden in Second Medical Use CasesThe UPC Central Division dismissed Biogaran's revocation action against Lundbeck's nalmefene patent for alcohol dependence on 9 October 2026, ordering Biogaran to pay EUR 100,000. The Court set rules requiring challengers to specify exactly where a patent fails, and refused to build obviousness cases from over ten documents without a pointer. The decision is a first-instance ruling, with an appeal possible.Real DealsBC Partners to acquire Biogaran in French carve-out deal with a €800m to €1bn EVBC Partners has entered into exclusive negotiations to acquire Biogaran, a French generic drug company, from the non-profit pharmaceutical group Servier. The enterprise value of the deal is estimated to be between €800 million and €1 billion. This acquisition represents a significant move in the healthcare sector in France.Les EchosInvestissements étrangers : les parlementaires veulent exercer plus de contrôleFrench parliamentarians are pushing for stronger control over foreign investments in France, holding a colloquium on June 10, 2026, dedicated to the topic of foreign investment control. LR MP Philippe Juvin launched a legislative bill in late March to expand sectors requiring government authorization, define conditions imposed on buyers, and strengthen parliamentary oversight. The initiative was driven by controversies over the sale of French company LMB Aerospace, a supplier of cooling systems for Rafale jets, to American Loar Group, and the sale of generic drug specialist Biogaran to British private equity firm BC Partners.RfiBiogaran sale talks renew fears over foreign control of French pharmaServier entered exclusive negotiations with UK fund BC Partners to sell its generic drug subsidiary Biogaran, with an offer potentially worth €800 million to €1 billion. The sale would reopen debates over France's health sovereignty amid drug shortages, and lawmakers warned it could weaken domestic drug-making capacity.